You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Reimbursement news and insurance coverage updates.
Myriad Genetics' EndoPredict, Agendia's MammaPrint (distributed in Germany by PathoNext), and Veracyte's Prosigna will now be covered by public insurance.
Once finalized, lung cancer patients in England can receive the drug for two years after they've received chemotherapy and if their tumors express PD-L1.
In a local coverage article, Medicare contractors in the MolDx program added prostate cancer to the covered indications for the test.
The diagnostic will be covered when patients are tested according to the Japanese Organization of Hereditary Breast and Ovarian Cancer's criteria.
The final national coverage decision stipulates that NGS germline tests for assessing hereditary breast and ovarian cancer risk must have FDA's blessing.